New combo aims to cut relapse in tough leukemia cases
NCT ID NCT07562568
First seen May 08, 2026 · Last updated May 08, 2026
Summary
This study tests whether adding two drugs (SHR2554 and azacitidine) before a stem cell transplant can lower the chance of leukemia coming back. It includes 160 people aged 15-60 with high-risk or hard-to-treat acute leukemia or myelodysplastic syndromes. Participants are randomly assigned to get the new drug combo or standard treatment, then all receive a stem cell transplant. The main goal is to see how many stay cancer-free for two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China
Conditions
Explore the condition pages connected to this study.